Xilio Therapeutics (NASDAQ:XLO) Shares Up 0.9% – Still a Buy?

Shares of Xilio Therapeutics, Inc. (NASDAQ:XLO) shot up 0.9% during mid-day trading on Monday . The stock traded as high as $0.5533 and last traded at $0.5458. 237,294 shares were traded during trading, a decline of 49% from the average session volume of 461,846 shares. The stock had previously closed at $0.5409.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xilio Therapeutics in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $2.00.

Xilio Therapeutics Trading Up 0.9%

The stock has a market cap of $36.86 million, a price-to-earnings ratio of -0.84 and a beta of -0.06. The company’s fifty day moving average is $0.65 and its two-hundred day moving average is $0.71.

Xilio Therapeutics (NASDAQ:XLO) last released its quarterly earnings results on Thursday, November 13th. The company reported ($0.03) EPS for the quarter, hitting the consensus estimate of ($0.03). The business had revenue of $19.07 million during the quarter, compared to analyst estimates of $18.64 million. Xilio Therapeutics had a negative return on equity of 679.66% and a negative net margin of 183.90%. Analysts predict that Xilio Therapeutics, Inc. will post -1.14 EPS for the current year.

Institutional Trading of Xilio Therapeutics

A hedge fund recently raised its stake in Xilio Therapeutics stock. Squarepoint Ops LLC grew its holdings in Xilio Therapeutics, Inc. (NASDAQ:XLO) by 39.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 328,794 shares of the company’s stock after purchasing an additional 93,338 shares during the quarter. Squarepoint Ops LLC owned 0.63% of Xilio Therapeutics worth $277,000 at the end of the most recent reporting period. 54.29% of the stock is owned by institutional investors.

Xilio Therapeutics Company Profile

Xilio Therapeutics is a clinical‐stage biotechnology company focused on the discovery and development of tumor‐targeted cytokine therapeutics for the treatment of cancer. The company leverages a proprietary platform to design pro‐drug versions of potent immune‐modulating cytokines, enabling local activation of immune responses within the tumor microenvironment while limiting systemic exposure and toxicity.

The company’s lead programs utilize engineered interleukin‐12 (IL‐12) and interleukin‐2 (IL‐2) molecules fused to tumor‐binding antibodies or peptide ligands.